Posts tagged as: new diabetes management technology back to homepage

Taglich Updates ALR Technologies, Maintains 50 Cent Price Target Taglich Updates ALR Technologies, Maintains 50 Cent Price Target(0)

Analyst firm Taglich Brothers has updated their research report on ALR Technologies (OTCBB: ALRT). The New York-based firm has maintained their 50 cent, 12-month price target on ALRT and “Speculative Buy” rating based on five-year revenue potential for the company. Shares of ALRT closed trading on Wednesday at $0.0795; ahead 13.57% from Tuesday’s closing price. Read More

Taglich Brothers Analyst Report on ALRT in PowerPoint Taglich Brothers Analyst Report on ALRT in PowerPoint(0)

Leading research firm Taglich Brothers has initiated coverage on ALR Technologies, Inc. (OTCBB: ALRT) with a 12-month price target set at 50 cents.  Shares are trading today at 8 cents.  ALR maintains a relatively low profile in the investment community, but Taglich apparently sees some substantial upside based on their extensive analyst report. Read More

Stay Informed

Receive the OTCS Newsletter *


* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

© 2011 Viper Enterprises, LLC. All rights reserved.